Want to see EYPT full AI Analyst Report?
Top Page
EyePoint Pharmaceuticals
(NASDAQ:EYPT)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.50
▼(-29.86% Downside)
Action:Reiterated
Date:09/10/26
The score is held down primarily by sharply deteriorating financial performance (revenue collapse, major margin compression, and very heavy cash burn) and a clear bearish technical trend with the stock far below key moving averages. Valuation offers limited support due to ongoing losses (negative P/E) and no dividend. Corporate events provide some upside from Phase 3 momentum, but legal/compliance actions and funding dependence keep overall risk elevated.
Positive Factors
Sustained-release retinal platform
DURAVYU’s sustained-release design targets a lower treatment burden in major retinal diseases, which could provide meaningful clinical differentiation if efficacy is maintained. The platform and room-temperature bioerodible insert also support a broader commercial proposition beyond a single trial or indication.
Negative Factors
Severe revenue and margin deterioration
The sharp contraction in revenue and gross margin indicates materially weaker earnings quality and limited visibility into near-term operating performance. Reliance on lumpy licensing or milestone income makes results less predictable, while reduced product contribution may constrain the company’s ability to fund development internally.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained-release retinal platform
DURAVYU’s sustained-release design targets a lower treatment burden in major retinal diseases, which could provide meaningful clinical differentiation if efficacy is maintained. The platform and room-temperature bioerodible insert also support a broader commercial proposition beyond a single trial or indication.
Read all positive factors
EyePoint Pharmaceuticals Key Performance Indicators (KPIs)
Any
Revenue Breakdown
Analyzes the sources of the company's revenue, highlighting key products or services that drive sales and indicating areas of growth or dependency.
Analyzes the sources of the company's revenue, highlighting key products or services that drive sales and indicating areas of growth or dependency.
Data provided by:
The Fly
The FlyEyePoint Pharmaceuticals (EYPT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$315.54M
Dividend YieldN/A
Average Volume (3M)5.49M
Price to Earnings (P/E)―
Beta (1Y)2.30
Revenue Growth-94.63%
EPS Growth-39.78%
CountryUS
Employees214
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.74
Shares Outstanding86,212,135
10 Day Avg. Volume2,733,513
30 Day Avg. Volume5,487,359
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)4.37
Price to Sales (P/S)42.66
P/FCF Ratio-5.50
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.40Price Target Upside409.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.72
Revenue Forecast (FY)$1.72M
EyePoint Pharmaceuticals Business Overview & Revenue Model
Company Description
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized produc...
How the Company Makes Money
EyePoint primarily generates revenue through (1) collaboration and licensing arrangements and (2) to a lesser extent product-related revenue where applicable, alongside other operating income items that can include contract-related payments. Colla...
EyePoint Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call conveyed robust clinical and operational momentum: imminent Phase III wet AMD readouts, strong DME enrollment, favorable Phase II data and a differentiated MOA, supported by manufacturing and commercial preparations. Offsetting this are steep year-over-year revenue decline (driven by prior deferred revenue recognition), rising operating expenses, a larger quarterly net loss and a notable quarter-over-quarter cash reduction. Management projects cash runway into Q4 2027, and masked safety data and DSMC recommendations to date are favorable. Overall, the clinical and strategic positives tied to near-term pivotal catalysts moderately outweigh the financial headwinds.Positive Updates
Imminent Phase III Wet AMD Readouts
Top-line data for pivotal Phase III LUGANO expected mid-year 2026 with LUCIA to follow shortly thereafter; company positions DURAVYU to potentially be first-to-market among sustained-release programs.
Negative Updates
Sharp YoY Revenue Decline
Total net revenue was $0.7 million for Q1 2026 versus $24.5 million for Q1 2025, a decline of approximately 97.1%, primarily due to recognition of remaining deferred revenue related to the 2023 YUTIQ license agreement.
Read all updates
Q1-2026 Updates
Positive
Negative
Imminent Phase III Wet AMD Readouts
Top-line data for pivotal Phase III LUGANO expected mid-year 2026 with LUCIA to follow shortly thereafter; company positions DURAVYU to potentially be first-to-market among sustained-release programs.
Read all positive updates
Company Guidance
On the call EyePoint reiterated clear operational and clinical guidance with many specific metrics: the company ended Q1 2026 with $223M in cash and investments (down from $306M at 12/31/25) and expects that cash to fund operations into Q4 2027; Q1 net revenue was $0.7M vs. $24.5M a year earlier, operating expenses were $88M vs. $73M, and net loss was $85M ($0.99/share) vs. $45M ($0.65/share). Clinically, Phase III LUGANO top-line wet AMD data are expected mid‑2026 with LUCIA to follow shortly thereafter, DME trials COMO and CAPRI are >1/3 enrolled with a goal of full enrollment in both pivotal DME trials in Q3 2026 and DME top-line data expected H2 2027; both pivotal programs use identical non‑inferiority designs versus on‑label 2 mg aflibercept with 6‑month redosing. Other program metrics highlighted: DURAVYU has shown durable efficacy across >190 patients in 4 completed trials with no safety signals, a low discontinuation rate of ~5% (well below the ~10% annual wet AMD trial average), all LUGANO/LUCIA patients have reached week 32 with >35% having received a planned third dose at week 56, the independent DMC has issued 2 positive reviews with a third scheduled this month, the cGMP Northbridge facility has been online >1 year supporting anticipated CMC/NDA activities, and the combined U.S. branded wet AMD+DME market opportunity is nearly $15B.EyePoint Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.79M | 31.37M | 43.27M | 46.02M | 41.40M | 36.94M |
| Gross Profit | 1.17M | 29.30M | 39.56M | 41.39M | 33.08M | 28.76M |
| EBITDA | -294.41M | -229.34M | -129.23M | -69.00M | -96.62M | -50.15M |
| Net Income | -306.64M | -231.96M | -130.87M | -70.80M | -102.25M | -58.42M |
Balance Sheet | ||||||
| Total Assets | 228.19M | 364.00M | 418.46M | 355.18M | 180.36M | 263.37M |
| Cash, Cash Equivalents and Short-Term Investments | 180.47M | 306.09M | 370.91M | 331.05M | 144.56M | 211.56M |
| Total Debt | 22.37M | 22.79M | 21.86M | 4.91M | 46.35M | 39.20M |
| Total Liabilities | 61.78M | 57.88M | 81.96M | 88.86M | 83.99M | 78.99M |
| Stockholders Equity | 166.41M | 306.11M | 336.50M | 266.32M | 96.37M | 184.38M |
Cash Flow | ||||||
| Free Cash Flow | -271.28M | -243.39M | -130.28M | -1.61M | -67.16M | -50.25M |
| Operating Cash Flow | -267.30M | -240.11M | -126.23M | 1.88M | -65.00M | -50.10M |
| Investing Cash Flow | 114.88M | 68.58M | -219.35M | -3.31M | -17.27M | -33.12M |
| Financing Cash Flow | 191.74M | 173.65M | 164.02M | 187.07M | -690.00K | 216.90M |
EyePoint Pharmaceuticals Technical Analysis
Negative
4.99
Price Trends
9.40
Negative
11.29
Negative
13.28
Negative
Market Momentum
-1.60
Negative
24.85
Positive
7.56
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EYPT, the sentiment is Negative. The current price of 4.99 is above the 20-day moving average (MA) of 4.64, below the 50-day MA of 9.40, and below the 200-day MA of 13.28, indicating a bearish trend. The MACD of -1.60 indicates Negative momentum. The RSI at 24.85 is Positive, neither overbought nor oversold. The STOCH value of 7.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EYPT.
EyePoint Pharmaceuticals Risk Analysis
EyePoint Pharmaceuticals disclosed 56 risk factors in its most recent earnings report. EyePoint Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
EyePoint Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.23B | 16.79 | 284.38% | ― | 948.35% | ― | |
54 Neutral | $403.92M | -3.62 | -196.63% | ― | 20.83% | 73.89% | |
52 Neutral | $620.19M | -5.84 | -42.92% | ― | ― | 34.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $336.91M | -3.95 | 1688.22% | ― | -3.66% | -28.98% | |
46 Neutral | $524.47M | -2.11 | -220.07% | ― | 12.00% | -9.21% | |
44 Neutral | $315.54M | -0.92 | -135.81% | ― | -94.63% | -39.78% |
* Healthcare Sector Average
EYPT
EyePoint Pharmaceuticals
3.45
-10.19
-74.71%
OCGN
Ocugen
1.00
-0.32
-24.39%
RGNX
RegenXBio
7.98
-1.05
-11.63%
EDIT
Editas Medicine
2.71
-0.01
-0.37%
MGTX
Meiragtx Holdings
12.76
5.43
74.08%
OCS
Oculis Holding
9.91
-7.49
-43.05%
EyePoint Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
EyePoint updates DURAVYU Phase 3 wet AMD data
Positive
Sep 10, 2026
EyePoint, Inc. operates in the ophthalmology and retinal disease space, focusing on sustained-release drug delivery technologies. Its lead product candidate DURAVYU is a vorolanib-based, tyrosine kinase inhibitor implant using the company’s ...
Business Operations and StrategyProduct-Related Announcements
EyePoint Reports Pivotal Phase 3 LUGANO Trial Results
Neutral
Aug 17, 2026
On August 17, 2026, EyePoint reported topline results from LUGANO, the first of two pivotal Phase 3 trials of DURAVYU 2.7 mg in wet age-related macular degeneration, showing that the drug was non-inferior to on-label aflibercept in an ad hoc analy...
Business Operations and StrategyProduct-Related Announcements
EyePoint completes Phase 3 DURAVYU enrollment for DME
Positive
Jul 30, 2026
On July 30, 2026, EyePoint announced it had completed enrollment in its pivotal global Phase 3 COMO and CAPRI trials of DURAVYU for diabetic macular edema, rapidly enrolling more than 480 patients in five months and ahead of schedule. The trials, ...
Business Operations and StrategyLegal ProceedingsRegulatory Filings and Compliance
EyePoint Pharmaceuticals Settles DEXYCU Case, Enhances Compliance Oversight
Negative
Jul 17, 2026
On July 17, 2026, EyePoint, Inc. entered into a settlement agreement with the U.S. Department of Justice, Office of Inspector General of HHS, the Defense Health Agency and a relator to resolve potential civil claims tied to alleged improper sales,...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
EyePoint Stockholders Approve Incentive Plan and Board Slate
Positive
Jun 22, 2026
EyePoint, Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026 via live webcast, with a quorum of 84.74% of the 83,795,203 eligible common shares participating. Stockholders approved an amendment to the 2023 Long-Term Incentive Plan ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.